NGVT
Ingevity CORP
NYSE
8-K: Ingevity Terminates Crude Tall Oil Supply Agreement with Georgia-Pacific for $100 Million
Sentiment:
Material Definitive Agreement Termination
8 July 2024 4:20 PM
Ingevity Corporation has agreed to pay Georgia-Pacific $100 million to terminate a long-term crude tall oil supply agreement, aiming for greater flexibility in its Performance Chemicals business.
Worse than expected
The company is paying a significant $100 million termination fee, which is a negative financial impact.
Summary
- Ingevity Corporation has terminated its Crude Tall Oil Supply Agreement with GP Pine Chemicals (Georgia-Pacific) effective July 1, 2024.
- The termination required Ingevity to pay Georgia-Pacific a total of $100 million, with $50 million paid on July 1, 2024, and the remaining $50 million due by October 15, 2024.
- In addition to the termination payment, Ingevity is obligated to purchase additional crude tall oil from Georgia-Pacific in July 2024 if June 2024 purchases did not meet certain volume thresholds.
- The agreement includes a mutual release of claims, covenants not to sue, and confidentiality provisions.
- The termination allows Ingevity to restructure its Performance Chemicals business segment, focusing on specialty chemicals markets.
Sentiment
Score: 4
Explanation: The document indicates a strategic shift with a significant financial cost. While the long-term goal is positive, the immediate impact is negative due to the large termination payment. The sentiment is therefore cautiously negative.
Positives
- The termination of the supply agreement provides Ingevity with greater flexibility to restructure its Performance Chemicals business segment.
- Ingevity can now focus on more attractive specialty chemicals markets.
- The agreement includes a mutual release of claims, reducing potential future legal liabilities related to the terminated contract.
Negatives
- Ingevity is required to pay a substantial $100 million termination fee to Georgia-Pacific.
- Ingevity may need to purchase additional crude tall oil in July 2024 if June purchases were below the agreed volume thresholds.
- The company will incur costs associated with the transition of the crude tall oil supply chain.
Risks
- Failure to make the second $50 million payment by October 15, 2024, could result in penalties, including interest, reinstatement of the supply agreement, or a $25 million liquidated damages payment.
- The restructuring of the Performance Chemicals business may involve unforeseen costs and challenges.
- The company faces risks related to general global economic conditions, competition, and supply chain disruptions.
Future Outlook
Ingevity plans to update investors on its restructuring plans for the Performance Chemicals business segment as decisions are made. The company is focusing on attractive specialty chemicals markets.
Management Comments
- Ingevity's management has been evaluating additional significant steps that could be taken in 2024 to restructure its Performance Chemicals business segment to focus it on attractive specialty chemicals markets.
- The termination of the CTO Supply Agreement provides additional flexibility in this regard.
Industry Context
The termination of the supply agreement reflects a strategic shift by Ingevity to focus on higher-margin specialty chemicals, potentially moving away from reliance on commodity-like crude tall oil. This could be a response to changing market dynamics or a move to improve profitability.
Comparison to Industry Standards
- Terminating long-term supply agreements is not uncommon when companies seek to restructure or change their strategic direction.
- The $100 million termination fee is significant and suggests a substantial commitment to the new strategy.
- Companies like Kraton Corporation and Eastman Chemical Company also operate in the specialty chemicals space and may be considered peers, although their specific supply chain strategies may differ.
Stakeholder Impact
- Shareholders will be impacted by the $100 million termination payment, but may benefit from the long-term strategic shift.
- Employees in the Performance Chemicals segment may experience changes due to the restructuring.
- Georgia-Pacific will receive a substantial payment and transition its crude tall oil supply chain.
Next Steps
- Ingevity will make a second $50 million payment to Georgia-Pacific by October 15, 2024.
- Ingevity will purchase additional crude tall oil from Georgia-Pacific in July 2024 if required.
- Ingevity will continue to evaluate and implement restructuring plans for its Performance Chemicals business.
- Ingevity will update investors on its restructuring plans as decisions are made.
Key Dates
- March 8, 2018: Original Crude Tall Oil Supply Agreement date.
- May 1, 2020: Date of the first amendment to the Crude Tall Oil Supply Agreement.
- March 1, 2023: Date of the second amendment to the Crude Tall Oil Supply Agreement.
- July 1, 2024: Effective date of the termination agreement and first $50 million payment.
- October 15, 2024: Date for the second $50 million payment and final termination of the agreement.
Keywords
Crude Tall Oil, Supply Agreement, Termination, Performance Chemicals, Georgia-Pacific, Restructuring, Specialty Chemicals, Ingevity
NGVT
Ingevity CORP
NYSE
Sector: TBD
Filings with Classifications
Worse than expected
6 May 2025 4:24 PM
Quarterly Report
- The company is adjusting the lower end of its previously disclosed outlook to Net sales between $1.25 billion and $1.4 billion for 2025.
- The adjusted EBITDA outlook, which has been adjusted to incorporate the ~10 percent reduction in North America light vehicle production, is expected to be between $380 million and $415 million for 2025.
Worse than expected
5 May 2025 4:17 PM
Quarterly Report
- The company has widened its full-year guidance range to reflect declines in industry forecasts of auto production due to trade tensions and tariff uncertainty, indicating worse than expected results.
Worse than expected
26 March 2025 3:07 PM
Proxy Statement
- Ingevity's Total Shareholder Return (TSR) has been worst-in-class compared to its peers.
- Key financial metrics like Net Debt, Financial Leverage, Free Cash Flow, and Return on Invested Capital (ROIC) have worsened over time.
- Vision One believes Ingevity has struggled to effectively implement its corporate strategy.
Better than expected
20 March 2025 9:30 PM
Definitive Proxy Statement
- Ingevity's 2024 financial results, including revenue, adjusted EBITDA, and cost savings, exceeded expectations.
- The company's free cash flow in 2024 was well above prior guidance.
- Ingevity's stock has outperformed the S&P 400 Chemicals Index since the announcement of the CEO search.
Better than expected
20 March 2025 8:15 PM
Proxy Statement
- The company's adjusted EBITDA exceeded analyst expectations.
- The company's EBITDA margins improved by 350 basis points.
- The company's Performance Materials segment delivered record performance.
Better than expected
25 February 2025 5:27 PM
Proxy Statement Communication
- Ingevity's Performance Materials segment achieved record performance with margins surpassing 50%, indicating better than expected results.
- The company realized $84 million in savings from Performance Chemicals repositioning, exceeding the initial target of $65-$75 million, which is better than expected.
- Ingevity's second half EBITDA margins increased to approximately 28% in 2024, and it delivered free cash flow that significantly exceeded prior guidance, indicating better than expected results.
Worse than expected
19 February 2025 4:18 PM
Annual Report
- The company reported a significant net loss compared to the previous year.
- The Performance Chemicals segment experienced a substantial goodwill impairment charge.
- Net sales decreased due to volume declines and repositioning actions.
Delay expected
19 February 2025 4:18 PM
Annual Report
- Final resolution of the intellectual property legal proceedings with BASF Corporation could take up to 15 months.
Worse than expected
18 February 2025 4:37 PM
Earnings Release
- The company reported a net loss of $430.3 million for the full year, including pre-tax charges of $688.0 million.
- Full year net sales decreased 17% year-over-year.
Better than expected
16 January 2025 6:32 AM
Strategic Review and Preliminary Results Announcement
- The company's full year Adjusted EBITDA is expected to reach the high end of previous guidance.
- Free cash flow is expected to significantly exceed prior guidance.
Worse than expected
30 October 2024 4:21 PM
Quarterly Report
- The company reported a net loss of $107.2 million in Q3 2024, compared to a net income of $25.2 million in Q3 2023.
- Net sales decreased by 15% year-over-year, primarily due to lower volumes in the Performance Chemicals segment.
- The company incurred significant restructuring and other charges, net of $86.9 million in Q3 and $162.8 million year-to-date.
- A goodwill impairment charge of $349.1 million was recorded in the second quarter of 2024.
Worse than expected
29 October 2024 4:20 PM
Quarterly Report
- The company reported a net loss of $107.2 million, significantly worse than the net income of $25.2 million in the same quarter last year.
- Net sales decreased by 16% year-over-year, indicating a decline in revenue performance.
- The company incurred substantial restructuring charges and contract termination fees, negatively impacting profitability.
Worse than expected
1 August 2024 4:18 PM
Quarterly Report
- The company reported a significant net loss due to a goodwill impairment charge and restructuring costs, indicating worse than expected financial performance.
- Net sales decreased significantly, particularly in the Performance Chemicals segment, reflecting weaker demand and the impact of strategic repositioning.
- The company incurred a substantial loss on CTO resales, further contributing to the worse than expected results.
Worse than expected
31 July 2024 4:26 PM
Quarterly Report
- The company reported a significant net loss of $283.7 million, primarily due to a goodwill impairment charge, which is worse than expected.
- The 19% decrease in net sales and 16% decrease in adjusted EBITDA also indicate worse than expected performance.
- The revised full-year guidance for sales and adjusted EBITDA is lower than previous expectations.
Worse than expected
8 July 2024 4:20 PM
Material Definitive Agreement Termination
- The company is paying a significant $100 million termination fee, which is a negative financial impact.
Worse than expected
2 May 2024 4:16 PM
Quarterly Report
- The company reported a net loss of $56 million, a significant downturn from the $50.7 million net income in the same period last year.
- Net sales decreased by 13.4% year-over-year, indicating weaker performance compared to the previous year.
- The company incurred substantial restructuring charges of $62.8 million, impacting overall profitability.
Worse than expected
1 May 2024 4:19 PM
Quarterly Report
- The company reported a net loss of $56.0 million and a 13% decrease in net sales, indicating worse than expected results compared to the prior year.
Worse than expected
11 March 2024 4:19 PM
Proxy Statement
- The document indicates that the company's adjusted EBITDA decreased 12% to $396.8 million, suggesting worse than expected financial performance.
Delay expected
22 February 2024 4:16 PM
Annual Results
- The closure of the DeRidder plant is expected to be completed by the end of the first half of 2024.
Worse than expected
22 February 2024 4:16 PM
Annual Results
- The company reported a net loss of $5.4 million for 2023, compared to a net income of $211.6 million in 2022.
- Adjusted EBITDA for 2023 was $396.8 million, down from $452.6 million in 2022.
- Gross profit decreased to $471.9 million in 2023, down from $570.1 million in 2022.
Worse than expected
21 February 2024 4:24 PM
Quarterly Report
- The company reported a net loss for both Q4 and the full year, which is worse than the prior year's net income.
- Adjusted EBITDA was down 17% in Q4 and 12% for the full year, indicating a decline in profitability.
- Diluted earnings per share were significantly lower in both Q4 and the full year compared to the prior year.
Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.